Buy Tirzepatide Peptide in Australia

Choose strength: 20 MG

20mg$249.9940mgPrice to confirm

Buy Tirzepatide in Australia from Macropus Peptides as a research-grade 20mg vial, priced and ready to order, with a 40mg vial quoted on request. Tirzepatide is a synthetic peptide of 39 amino acids that activates two incretin receptors, GIP and GLP-1, from a single chain, and a fatty acid side chain lets it bind albumin so it stays in circulation for days. That dual action makes it the reference compound for laboratories comparing single, dual and triple incretin agonists. Each vial holds lyophilised powder under a crimped seal, labelled with compound, strength, lot number and storage temperature, and a certificate of analysis is available for every lot. Order online, add bacteriostatic water for reconstitution, and the parcel ships from Australia to any address in the country. Sold to researchers aged 18 and over for in-vitro laboratory work only, never for human or veterinary use.

Compound	Tirzepatide
Amount	20 mg
Form	Lyophilised powder
Category	Metabolic research
Storage	-20 °C, protect from light
Testing	HPLC purity and mass spectrometry identity, every batch
Certificate of analysis	Available for every lot, matched to the lot number on the label

Tirzepatide 20mg vial

Enter the diluent volume added to this vial to see the solution concentration. Laboratory calculation only, not dosing guidance.

Diluent added (mL)

Buy Tirzepatide Australia: 20mg and 40mg Vials

Macropus Peptides stocks this dual incretin agonist as a 20mg vial at a fixed price, with a 40mg vial available on quote for bigger programmes. Both sizes are freeze-dried research material drawn from one controlled supply and released lot by lot, so switching between them alters the amount of peptide and nothing else.

Tirzepatide Australia: what is Tirzepatide

Tirzepatide, coded LY3298176 during development, is a synthetic peptide of 39 amino acids built mostly on the sequence of GIP, the glucose-dependent insulinotropic polypeptide released by cells of the upper gut. Several positions were altered so that the same chain also switches on the GLP-1 receptor, which is why it is called a dual GIP and GLP-1 receptor agonist. A C20 fatty diacid, joined to the chain through a linker, lets the molecule ride on albumin in the bloodstream, and human pharmacokinetic studies recorded a half-life of about five days. It was the first dual incretin agonist of its type to complete a full clinical programme, and it is now the benchmark that newer multi-receptor peptides such as Retatrutide are measured against in the lab.

How Tirzepatide peptide acts on two incretin receptors

GIP and GLP-1 are the two incretin hormones, gut signals that amplify insulin secretion from pancreatic beta cells when glucose is raised. Each acts through its own receptor, and both receptors couple to the Gs protein and raise cyclic AMP inside the cell. The peptide is described as imbalanced because it activates the GIP receptor about as strongly as native GIP does, while its activity at the GLP-1 receptor is several times weaker than native GLP-1. At the GLP-1 receptor it is also biased: it favours cyclic AMP production over recruitment of beta-arrestin, the protein that pulls receptors into the cell, so less of the receptor is internalised. Laboratories use it to separate the contribution of each incretin receptor, to study signalling bias, and as the dual-agonist comparator in panels that also hold single GLP-1 agonists and a triple agonist.

Tirzepatide research: what the published studies show

Its discovery report, with the first human pharmacology, was published by Molecular Metabolism in 2018, while The Lancet ran a phase 2 study that year in people living with type 2 diabetes. The imbalanced and biased receptor profile was set out in JCI Insight in 2020, and cryo-electron microscopy structures of the peptide bound to both receptors followed in PNAS in 2022, showing how one chain fits two different binding pockets and where the lipid moiety sits. A phase 3 programme came next; its first monotherapy trial, published in The Lancet in 2021, measured glycated haemoglobin and fasting glucose against placebo. Designs, models and measurements for each paper are collected in our Tirzepatide research studies library.

Tirzepatide vial specifications

Inside the glass is a pale, freeze-dried cake of dual agonist beneath an aluminium crimp. Printed details cover compound, milligram strength, lot code and storage temperature. Email that lot code and we return the matching certificate. Until the study starts, park the sealed dual agonist at -20 °C behind an opaque lid.

Tirzepatide price and Tirzepatide cost in Australia

A listed Australian dollar figure applies to the 20mg vial, which ships from stock. The 40mg vial has no list figure yet: ask and we quote it against the lot we currently hold. A bigger vial of one peptide usually lowers the cost per milligram, so weigh that quote against buying a pair of 20mg vials.

Tirzepatide 20mg: where to buy in Australia

Twenty milligrams is the size most incretin laboratories choose, and the only one sold at a set price today. It carries a method build and a full receptor assay series on one lot, which is useful because albumin binding of this lipidated chain in serum-containing media is best measured once and then kept constant. Typical stock volumes for this vial:

• 2 mL: 10 mg per mL
• 4 mL: 5 mg per mL

Tirzepatide 40mg: larger vial, price on request

Twice the peptide of the smaller size in one container, meant for long or multi-arm studies where every data point should trace to one batch. Because it is quoted rather than listed, send an enquiry first and we confirm figure and stock. Four millilitres of diluent brings the 40mg Tirzepatide vial to 10 mg per mL, identical to its smaller sibling made up with half that volume, so pipetting plans transfer directly.

Best place to buy Tirzepatide Australia

• A fixed-price 20mg vial ready to order, and a 40mg vial on quote
• Both sizes filled from a single controlled supply
• Every label carries a lot code tied to its certificate
• Stock held in Australia, so parcels never wait at international customs
• Single and triple agonist comparators available in the same parcel

Tirzepatide how to get: buy Tirzepatide online

• Pick the 20mg vial, or ask us to quote 40mg
• Enter how many vials the study needs
• Tick bacteriostatic water if the lab is out
• Pay, declaring adult age and a laboratory purpose
• Log the lot code when the parcel lands and request its certificate

Tirzepatide calculator: bac water for 20mg and 40mg vials

Our concentration calculator, attached to the product listing, converts whatever diluent volume you enter into a stock strength for the vial you bought, shown in both milligram and microgram terms. Quick reference points for the 20mg vial:

• 2 mL: 10 mg per mL
• 4 mL: 5 mg per mL

And for the 40mg vial:

• 2 mL: 20 mg per mL
• 4 mL: 10 mg per mL

Let bacteriostatic water 10mL trickle down the glass rather than onto the cake, then swirl slowly until clear. Syringes and swabs sit under lab supplies.

Is Tirzepatide available in Australia

Registered medicines containing this compound hold ARTG entries and reach people only through medical channels. What we sell is different: unformulated research-grade peptide for in-vitro work, never to be given to a person or an animal. The compound itself is a scheduled substance under the Poisons Standard, so confirm how its current entry affects your organisation before placing an order.

Tirzepatide for sale Australia wide

Vials travel upright with the crimp shielded, bound for capital cities and country addresses alike. Laboratories building an incretin panel often add Retatrutide as the triple agonist and Cagrilintide for the amylin pathway, while the Tirzepatide starter kit adds 3 mL of bacteriostatic water, ten syringes and swabs to a 20mg vial. The complete metabolic research range sits alongside.

Questions about Tirzepatide